
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Bio-Optronics and Synexus announce partnership aimed at improving patient access to modern medicine and clinical trial efficiency by delivering high numbers of quality patients to clinical trials through the use of a unified CTMS across the entire Synexus network of more than 200 sites in eleven countries worldwide.
Read the full release






